FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809182872> ?p ?o ?g. }

• W2809182872 endingPage "998" @default.
• W2809182872 startingPage "988" @default.
• W2809182872 abstract "Anthracyclines, such as doxorubicin, are used as first-line chemotherapeutics, usually in combination therapies, for the treatment of advanced breast cancer. While these drugs have been successful therapeutic options, their use is limited due to serious drug related toxicities and acquired tumor resistance. Uncovering the molecular mechanisms that mediate doxorubicin's cytotoxic effect will lead to the identification of novel more efficacious combination therapies and allow for reduced doses of doxorubicin to be administered while maintaining efficacy. In our study, we demonstrate that activating transcription factor (ATF) 3 expression was upregulated by doxorubicin treatment in a representative panel of human breast cancer cell lines MCF7 and MDA-MB-231. We have also shown that doxorubicin treatment can induce ATF3 expression in ex vivo human breast and ovarian tumor samples. The upregulation of ATF3 in the cell lines was regulated by multiple cellular mechanisms including the activation of JNK and ATM signaling pathways. Importantly, loss of ATF3 expression resulted in reduced sensitivity to doxorubicin treatment in mouse embryonic fibroblasts. Through a 1200 FDA-approved compound library screen, we identified a number of agents whose cytotoxicity is dependent on ATF3 expression that also enhanced doxorubicin induced cytotoxicity. For example, the combination of the HDAC inhibitor vorinostat or the nucleoside analogue trifluridine could synergistically enhance doxorubicin cytotoxicity in the MCF7 cell line. Synergy in cell lines with the combination of ATF3 inducers and patients with elevated basal levels of ATF3 shows enhanced response to chemotherapy. Taken together, our results demonstrate a role for ATF3 in mediating doxorubicin cytotoxicity and provide rationale for the combination of ATF3-inducing agents with doxorubicin as a novel therapeutic approach." @default.
• W2809182872 created "2018-06-29" @default.
• W2809182872 creator A5039075996 @default.
• W2809182872 creator A5044146927 @default.
• W2809182872 creator A5058218845 @default.
• W2809182872 creator A5061917666 @default.
• W2809182872 creator A5091021820 @default.
• W2809182872 date "2018-08-01" @default.
• W2809182872 modified "2023-09-26" @default.
• W2809182872 title "Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer" @default.
• W2809182872 cites W1543790510 @default.
• W2809182872 cites W1763737827 @default.
• W2809182872 cites W1968417785 @default.
• W2809182872 cites W1977529605 @default.
• W2809182872 cites W1980850901 @default.
• W2809182872 cites W1983661160 @default.
• W2809182872 cites W1983661286 @default.
• W2809182872 cites W1994930469 @default.
• W2809182872 cites W1997993394 @default.
• W2809182872 cites W2021509563 @default.
• W2809182872 cites W2022715137 @default.
• W2809182872 cites W2025220605 @default.
• W2809182872 cites W2027169471 @default.
• W2809182872 cites W2027531487 @default.
• W2809182872 cites W2027821655 @default.
• W2809182872 cites W2030503662 @default.
• W2809182872 cites W2033013430 @default.
• W2809182872 cites W2045370737 @default.
• W2809182872 cites W2046406848 @default.
• W2809182872 cites W2056718629 @default.
• W2809182872 cites W2068577449 @default.
• W2809182872 cites W2069708743 @default.
• W2809182872 cites W2076265695 @default.
• W2809182872 cites W2084016080 @default.
• W2809182872 cites W2085934079 @default.
• W2809182872 cites W2086981199 @default.
• W2809182872 cites W2099814384 @default.
• W2809182872 cites W2120955132 @default.
• W2809182872 cites W2135085078 @default.
• W2809182872 cites W2141723876 @default.
• W2809182872 cites W2142827509 @default.
• W2809182872 cites W2153899204 @default.
• W2809182872 cites W2203051527 @default.
• W2809182872 cites W2235573011 @default.
• W2809182872 cites W2292755930 @default.
• W2809182872 cites W2511788166 @default.
• W2809182872 cites W2520354492 @default.
• W2809182872 cites W2521615731 @default.
• W2809182872 cites W2580029513 @default.
• W2809182872 cites W2588031139 @default.
• W2809182872 doi "https://doi.org/10.1016/j.tranon.2018.06.001" @default.
• W2809182872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6039300" @default.
• W2809182872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29940414" @default.
• W2809182872 hasPublicationYear "2018" @default.
• W2809182872 type Work @default.
• W2809182872 sameAs 2809182872 @default.
• W2809182872 citedByCount "21" @default.
• W2809182872 countsByYear W28091828722019 @default.
• W2809182872 countsByYear W28091828722020 @default.
• W2809182872 countsByYear W28091828722021 @default.
• W2809182872 countsByYear W28091828722022 @default.
• W2809182872 countsByYear W28091828722023 @default.
• W2809182872 crossrefType "journal-article" @default.
• W2809182872 hasAuthorship W2809182872A5039075996 @default.
• W2809182872 hasAuthorship W2809182872A5044146927 @default.
• W2809182872 hasAuthorship W2809182872A5058218845 @default.
• W2809182872 hasAuthorship W2809182872A5061917666 @default.
• W2809182872 hasAuthorship W2809182872A5091021820 @default.
• W2809182872 hasBestOaLocation W28091828721 @default.
• W2809182872 hasConcept C101762097 @default.
• W2809182872 hasConcept C104317684 @default.
• W2809182872 hasConcept C109316439 @default.
• W2809182872 hasConcept C126322002 @default.
• W2809182872 hasConcept C127561419 @default.
• W2809182872 hasConcept C150194340 @default.
• W2809182872 hasConcept C157880135 @default.
• W2809182872 hasConcept C202751555 @default.
• W2809182872 hasConcept C2776694085 @default.
• W2809182872 hasConcept C2781303535 @default.
• W2809182872 hasConcept C502942594 @default.
• W2809182872 hasConcept C55493867 @default.
• W2809182872 hasConcept C71924100 @default.
• W2809182872 hasConcept C77179829 @default.
• W2809182872 hasConcept C86339819 @default.
• W2809182872 hasConcept C86803240 @default.
• W2809182872 hasConcept C98274493 @default.
• W2809182872 hasConceptScore W2809182872C101762097 @default.
• W2809182872 hasConceptScore W2809182872C104317684 @default.
• W2809182872 hasConceptScore W2809182872C109316439 @default.
• W2809182872 hasConceptScore W2809182872C126322002 @default.
• W2809182872 hasConceptScore W2809182872C127561419 @default.
• W2809182872 hasConceptScore W2809182872C150194340 @default.
• W2809182872 hasConceptScore W2809182872C157880135 @default.
• W2809182872 hasConceptScore W2809182872C202751555 @default.
• W2809182872 hasConceptScore W2809182872C2776694085 @default.
• W2809182872 hasConceptScore W2809182872C2781303535 @default.
• W2809182872 hasConceptScore W2809182872C502942594 @default.
• W2809182872 hasConceptScore W2809182872C55493867 @default.

• next